RxDoctor Payments Data

Terri Nickel, DO

Family Medicine · Wichita, KSNPI 1902867831

Payments from drug & device makers

$369in general payments, 2019–2025

Across 16 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$122
  • Johnson & Johnson$50
  • Lilly USA, LLC$46
  • Novo Nordisk$41
  • Merck$26
  • Pfizer$24
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$35596%
  • Education$144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$369 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$68,773
Medicare patients
227
Services billed
1,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$122,145
EliquisApixaban56$49,632
JanuviaSitagliptin Phosphate30$34,351
JardianceEmpagliflozin38$32,834
MyrbetriqMirabegron48$26,547
FycompaPerampanel19$24,705
Tresiba Flextouch U-200Insulin Degludec17$22,808
OxycontinOxycodone Hcl16$21,265
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$20,476
EntrestoSacubitril/Valsartan21$19,841
Tresiba Flextouch U-100Insulin Degludec33$18,080
PentasaMesalamine12$17,581
MounjaroTirzepatide16$16,534
TradjentaLinagliptin28$14,446
XareltoRivaroxaban12$14,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$122,14582 claims
PfizerEliquis, Prempro$24$52,75669 claims
MerckJanuvia, Janumet Xr$26$46,45054 claims
Lilly USA, LLCMounjaro, Trulicity$46$28,89729 claims
Johnson & JohnsonXarelto$50$14,34712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →